FDA Novel Drug Therapy Approvals 2026: Quarter 1
The first quarter of 2026 has marked a significant start in pharmaceutical innovation, with the FDA approving multiple novel therapies across oncology, rare genetic disorders, dermatology, and metabolic diseases. These approvals reflect continued progress in targeted treatments, biologics, and therapies addressing unmet medical needs.
Below is a comprehensive list of FDA novel drug therapy approvals for Quarter 1 (January–March) 2026, including drug names, active ingredients, approval dates, and approved indications.
FDA Novel Drug Approvals – Q1 2026
- Lifyorli (relacorilant) — Approved on March 25, 2026, to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, including at least one with bevacizumab.
- Avlayah (tividenofusp alfa-eknm) — Approved on March 24, 2026, to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
- Icotyde (icotrokinra) — Approved on March 17, 2026, for the treatment of moderate-to-severe plaque psoriasis in patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
- Lynavoy (linerixibat) — Approved on March 17, 2026, to treat cholestatic pruritus associated with primary biliary cholangitis.
- Yuviwel (navepegritide) — Approved on February 27, 2026, to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses.
- Loargys (pegzilarginase-nbln) — Approved on February 23, 2026, to treat hyperarginemia in adults and pediatric patients aged two years and older with Arginase 1 Deficiency, alongside dietary protein restriction.
- Bysanti (milsaperidone) — Approved on February 20, 2026, for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.
- Adquey (difamilast) — Approved on February 12, 2026, to treat mild to moderate atopic dermatitis.
- Zycubo (copper histidinate) — Approved on January 12, 2026, for the treatment of Menkes disease.
The FDA approvals in the first quarter of 2026 demonstrate a strong emphasis on rare diseases, dermatological conditions, and oncology. Notably, several therapies target genetic and metabolic disorders, highlighting the growing role of precision medicine and biologics in modern healthcare.
Source: FDA Novel Drug Approvals 2026
FDA Novel Drug Approvals
2024: https://biopatrika.com/industry/regulatory/novel-drug-approvals-for-2024-fda/
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
